Christine E. Engeland

Author

Heidelberg University ORCID

Also Known As

C E Engeland, C.E. Engeland, Christine E Engeland, Christine E. Engeland, Christine Engeland, Engeland, Christine E.

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Heidelberg University University Hospital Heidelberg National Center for Tumor Diseases German Cancer Research Center Ottawa Hospital

About

Christine E. Engeland is an author at Heidelberg University specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	286
2	Immunology	7	7	226
3	Engineering	2	2	24
4	Cell Biology	2	2	138
5	Allergy	1	1	12

Christine E. Engeland

Publications

981

Citations

H-Index

Page 1

	Year	Citations
CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy Christine E. Engeland, Christian Grossardt, Rūta Veinalde, Molecular Therapy	2014	281
Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors Tobias Speck, Johannes P.W. Heidbuechel, Rūta Veinalde, Clinical Cancer Research	2018	98
Granulocyte-Macrophage Colony-Stimulating Factor-Armed Oncolytic Measles Virus Is an Effective Therapeutic Cancer Vaccine Christian Grossardt, Christine E. Engeland, Sascha Bossow, Human Gene Therapy ImmunologyImmunoeditingImmunotherapeuticsImmune Cell TherapyImmunotherapy	2013	95
Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation Rūta Veinalde, Christian Grossardt, Laura Hartmann, OncoImmunology	2017	76
MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus Marc-Andrea Baertsch, Mathias F. Leber, Sascha Bossow, Cancer Gene Therapy Viral ReplicationPathologyVirologyOncolytic Measles VirusMicrorna Detection	2014	60
Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors Johanna Reul, Janina Frisch, Christine E. Engeland, Frontiers in Oncology	2019	58
A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol Jacek Hajda, Monika Lehmann, Ottheinz Krebs, BMC Cancer	2017	44
Immunological Effects and Viral Gene Expression Determine the Efficacy of Oncolytic Measles Vaccines Encoding IL-12 or IL-15 Agonists Rūta Veinalde, Laura Hartmann, Jessica Dunder, Viruses ImmunologyImmunoeditingImmunologic MechanismImmunotherapeuticsCd4 T Cell Responses	2019	43
Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Jacek Hajda, Barbara Leuchs, Assia L. Angelova, Clinical Cancer Research	2021	38
Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites Mathias F. Leber, Marc-Andrea Baertsch, Sophie C. Anker, Molecular Therapy — Oncolytics	2018	37

Page 1